Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cognition Therapeutics, Inc. - Common Stock (NQ: CGTX )

0.5901 +0.0001 (+0.02%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cognition Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump
Via Benzinga
Exposures Fossil Fuels
Tivic Health Systems (TIVC) Stock Pops Another 39%
Tivic Health Systems stock is up on Monday with heavy trading of TIVC shares as recent volatility continues for the company's units. 
Via InvestorPlace
Cognition Therapeutics Stock Tumbles On Mixed Data From Mid-Stage Alzheimer's Study
Cognition Therapeutics' Phase 2 'SHINE' study shows CT1812 leads to cognitive improvement in Alzheimer's patients over six months. Participants showed better performance on cognitive and functional... 
Via Benzinga
Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?
NLS Pharmaceutics stock is up on Monday after the company provided NLSP investors with details on a merger deal with Kadimastem. 
Via InvestorPlace
Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today?
Cognition Therapeutics stock is down on Monday after CGTX investors read the latest data from a Phase 2 clinical trial report. 
Via InvestorPlace
A Preview Of Cognition Therapeutics's Earnings
Via Benzinga
Nasdaq Gains 1%; McDonald's Posts Downbeat Results
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning! 
Via InvestorPlace
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
From Cognition Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q1 2024
CGTX stock results show that Cognition Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
- Top-line Results Expected in the Second Half of 2024 - 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
From Cognition Therapeutics, Inc.
Via GlobeNewswire
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q4 2023
CGTX stock results show that Cognition Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. 
Via Benzinga
BioMedNewsBreaks – Cognition Therapeutics Inc. (NASDAQ: CGTX) Closes on $11.5M Public Offering
Via Investor Brand Network
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
Conference Call and Live Audio Webcast Scheduled for March 26, 2024 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed lower by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and... 
Via Benzinga
Topics Stocks
Exposures US Equities
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
From Cognition Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
From Cognition Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.